Also, while the distinction in sensitivity between BRCA1 and BRCA2-associated ovarian cancers remains unclear in the clinical setting, emerging in vitro data does indicate that all BRCA mutations are not equal in their functionality. The gene discussed is BRCA2; the disease is ovarian cancer.